Search

Search Constraints

You searched for: Author/Creator Stoops, Erik

Search Results

61. P4‐705: TOWARD RE‐CALIBRATION OF COMMERCIAL IMMUNOASSAYS USING CERTIFIED REFERENCE MATERIALS FOR Aβ42 IN HUMAN CEREBROSPINAL FLUID. (1st July 2019)

63. Phospho‐specific plasma p‐tau181 assay detects clinical as well as asymptomatic Alzheimer's disease. Issue 5 (3rd May 2022)

64. Plasma Aβ (Amyloid-β) Levels and Severity and Progression of Small Vessel Disease. Issue 4 (April 2018)

65. Plasma biomarkers predict amyloid pathology in cognitively unimpaired individuals: Biomarkers (non‐neuroimaging): Blood based biomarkers. (7th December 2020)

66. Plasma pTau181/Aβ42 identifies cognitive change earlier than CSF pTau181/Ab42. (20th December 2022)

67. Plasma p‐tau181 concentration accurately predicts clinically diagnosed Alzheimer's Disease cases. (20th December 2022)

68. Plasma P‐tau181 levels predict amyloid pathology in cognitively unimpaired individuals after 10 years. (31st December 2021)

69. Plasma p‐tau181/Aβ1‐42 ratio predicts Aβ‐PET status and correlates with CSF‐p‐tau181/Aβ1‐42 and future cognitive decline. Issue 1 (25th November 2022)

70. Predictive value of a plasma p‐tau181‐specific assay for amyloid accumulation in asymptomatic Alzheimer's Disease. (20th December 2022)